Expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022).
10.3760/cma.j.cn112139-20220105-00009
- VernacularTitle:门静脉高压合并肝癌的临床诊疗专家共识（2022版）
- Collective Name:Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association
- Publication Type:Journal Article
- MeSH:
Carcinoma, Hepatocellular/therapy*;
Consensus;
Humans;
Hypertension, Portal/therapy*;
Liver Cirrhosis/complications*;
Liver Neoplasms/therapy*
- From:
Chinese Journal of Surgery
2022;60(4):310-320
- CountryChina
- Language:Chinese
-
Abstract:
At present, there is no uniform standard for diagnosis and treatment of portal hypertension complicated with hepatocellular carcinoma internationally. Although in recent years, with the significant advances of surgical technique and the positive progress of targeted and immunotherapy in the field of hepatocellular carcinoma, the survival of hepatocellular carcinoma patients has improved, but the risk of surgery in patients with portal hypertension complicated with hepatocellular carcinoma remains high, and surgical treatment is still controversial. Therefore, based on the existing evidence, the Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association has organized relevant experts to develop the consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022) after full discussion. This consensus aims to provide the latest guidance for the standardized diagnosis and treatment of portal hypertension with hepatocellular carcinoma in China. Given that most portal hypertension originates from cirrhosis, this consensus only addresses the diagnosis and treatment of cirrhosis-related portal hypertension with hepatocellular carcinoma.
